Division of Nephrology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-Ku, Saitama City, Saitama, 330-8777, Japan.
Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
Pediatr Nephrol. 2024 Feb;39(2):473-482. doi: 10.1007/s00467-023-06108-4. Epub 2023 Aug 22.
Although evidence has confirmed that cyclosporine (CS) is efficacious against childhood-onset steroid-dependent and steroid-resistant nephrotic syndrome (SD/SRNS), some patients may continue to relapse during adulthood. However, predictive factors for adult active disease and kidney complications, such as chronic kidney disease (CKD) and hypertension, in this cohort remain unknown.
We conducted a retrospective study on the long-term outcomes of 81 young adults with childhood-onset SD/SRNS treated with CS. The primary endpoint was the probability of active disease into adulthood. The secondary endpoint was the probability of developing kidney complications.
At the last follow-up (median age, 23.2 years; median disease duration, 15.8 years), 44 adult patients (54%) continued to have active disease, whereas 16 patients developed CKD or hypertension, respectively. The proportion of patients developing kidney complications was similar between the active disease and long-term remission groups. Young age at NS onset and history of relapse during the initial CS (median, 31 months) were independent predictive factors for active disease. Acute kidney injury at NS onset, focal segmental glomerulosclerosis, and irreversible CS nephrotoxicity were identified as risk factors for the development of CKD, whereas older age was identified as a risk factor for the development of CKD and hypertension.
More than 50% of adult survivors treated with CS continued to have active disease, and each 20% developed CKD or hypertension. A long-term follow-up is necessary for patients with SD/SRNS to identify the development of kidney complications later in adulthood that can be attributed to prior disease and CS treatment in childhood, irrespective of disease activity. A higher resolution version of the Graphical abstract is available as Supplementary information.
虽然有证据表明环孢素(Cs)对儿童期起病的激素依赖性和激素抵抗性肾病综合征(SD/SRNS)有效,但部分患者在成年后可能仍会复发。然而,该队列中成人活动性疾病和肾脏并发症(如慢性肾脏病(CKD)和高血压)的预测因素尚不清楚。
我们对 81 例接受 Cs 治疗的儿童期起病 SD/SRNS 成年患者进行了回顾性研究。主要终点是成年后疾病活动的概率。次要终点是发生肾脏并发症的概率。
在最后一次随访(中位年龄 23.2 岁;中位疾病持续时间 15.8 年)时,44 例成人患者(54%)仍有活动性疾病,而 16 例患者分别发展为 CKD 或高血压。在活动性疾病组和长期缓解组中,发生肾脏并发症的患者比例相似。NS 发病时年龄较小和 CS 初始复发史(中位 31 个月)是疾病活动的独立预测因素。NS 发病时急性肾损伤、局灶节段性肾小球硬化和不可逆 Cs 肾毒性被确定为 CKD 发生的危险因素,而年龄较大则被确定为 CKD 和高血压发生的危险因素。
超过 50%的接受 Cs 治疗的成年幸存者仍有活动性疾病,每 20%的患者发生 CKD 或高血压。SD/SRNS 患者需要长期随访,以识别成年后因既往疾病和儿童期 Cs 治疗而导致的肾脏并发症的发生,而与疾病活动无关。更清晰的图文摘要可在补充信息中查看。